Loading stock data…
BioMarin Pharmaceutical Inc. (BMRN)
$64.63-1.90 (-2.86%)
Market ClosedLast close Sep 8
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioMarin Pharmaceutical Inc. in the Healthcare sector is trading at $64.63 with a market capitalization of $10.6B. Wall Street consensus targets $91.42 (26 analysts), implying a +41.5% move over the next 12 months. The stock is currently 9% below its 52-week high of $70.98, remaining 11.6% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +41.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $989.71M↑ | $766.21M↓ | $874.57M↑ | $776.13M↓ | $825.41M |
| Gross Profit | $786.91M↑ | $571.21M↓ | $598.86M↓ | $636.05M↓ | $675.32M |
| Operating Income | $110.97M↓ | $129.63M↑ | -$44.60M↑ | -$46.68M↓ | $276.87M |
| Net Income | $44.76M↓ | $105.53M↑ | -$46.57M↓ | -$30.74M↓ | $240.53M |
Peer Comparison
JNJUNHPFE
Fundamentals
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Paci...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$10.56B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
39.32
Beta
Defensive asset. Lower volatility than the S&P 500.
0.23
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
4.33%
Volume
Today's trading volume
1.46M
Recent News
3 Reasons to Avoid BMRN and 1 Stock to Buy Instead
BioMarin Pharmaceutical trades at $66.53 and has moved in lockstep with the market. Its shares have returned 9.3% over the last six months while the S&P 500 has gained 13.6%.
3 Value Stocks We Think Twice About
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason, and a low valuation can reflect underlying business challenges rather than a genuine bargain.
BioMarin (BMRN) Secured 20% U.S. Royalties on Yuviwel. Is Monetizing a Rival Better than Blocking It?
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has converted a global patent dispute with Ascendis Pharma A/S (NASDAQ:ASND) into a royalty-bearing license for Yuviwel, a once-weekly treatment approved to increase linear growth in children aged 2 years and older with achondroplasia and open epiphyses. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will receive royalties equal to 20% of U.S. Yuviwel net […]
RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout
Wall Street removed the Angelman program from valuation models, slashing price targets by as much as 76% and issuing multiple downgrades.
Ascendis Pharma (ASND) Settles Patent Fight And Wins Canadian Yorvipath Reimbursement Backing
Ascendis Pharma (NasdaqGS:ASND) reached a global settlement and licensing agreement with BioMarin Pharmaceutical that resolves worldwide patent disputes related to Yuviwel. The deal grants Ascendis Pharma a license to continue commercializing Yuviwel and related products across global markets. Ascendis Pharma also received a positive reimbursement recommendation in Canada for Yorvipath for adults with chronic hypoparathyroidism. These legal and reimbursement outcomes affect Ascendis Pharma's...